OncoMed Pharmaceuticals, Inc.
OMED
OMED was delisted on the 22nd of April, 2019.
58 hedge funds and large institutions have $88.1M invested in OncoMed Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 23 reducing their positions, and 16 closing their positions.
3,650% more call options, than puts
Call options by funds: $75K | Put options by funds: $2K
35% more capital invested
Capital invested by funds: $65.4M → $88.1M (+$22.7M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less funds holding
Funds holding: 68 → 58 (-10)
22% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 23
56% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$4.21M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$632K |
| 3 |
D.E. Shaw & Co
New York
|
+$415K |
| 4 |
PP
PDT Partners
New York
|
+$376K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$360K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$17.8M |
| 2 |
ASP
Adams Street Partners
Chicago,
Illinois
|
-$1.49M |
| 3 |
Goldman Sachs
New York
|
-$579K |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$561K |
| 5 |
Two Sigma Investments
New York
|
-$436K |
OMED Hedge Fund Activity: Q3 2017 in Review
58 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q3 2017, worth a combined $88.1M — up 35% from $65.4M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of OMED and 7 opened new positions — a net loss of 9 holders — while 23 trimmed existing stakes and 18 added.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $4.21M. The largest seller was BVF Inc, exiting entirely with an estimated $17.8M sold.
- 58 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q3 2017, down from 68 in Q2 2017.
- Funds reported $88.1M of OncoMed Pharmaceuticals, Inc. stock for Q3 2017, up 35% quarter-over-quarter.
- 7 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q3 2017 and 16 closed out, a net change of -9 holders.
- The largest OncoMed Pharmaceuticals, Inc. buyer in Q3 2017 was Perceptive Advisors, an estimated $4.21M added.
- The largest OncoMed Pharmaceuticals, Inc. seller in Q3 2017 was BVF Inc, an estimated $17.8M sold.
Based on aggregated 13F filings for Q3 2017.